Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,776.50
Bid: 1,776.50
Ask: 1,777.50
Change: -1.50 (-0.08%)
Spread: 1.00 (0.056%)
Open: 1,780.00
High: 1,793.50
Low: 1,766.50
Prev. Close: 1,778.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday preview: GlaxoSmithKline to report difficult quarter, analysts say

Tue, 05th Feb 2013 15:01

Healthcare giant GlaxoSmithKline is expected to report 'another difficult quarter' when the company unveils its latest results Wednesday, according to analysts.The pharmaceuticals group will post its full-year and fourth quarter financials, a day after announcing it increased its stake in its Indian consumer healthcare subsidiary by investing more than half a billion pounds in the unit. "We expect another difficult quarter as the company experiences some tough [year on year] comparisons [Advair & Cervarix], EU austerity and a forex headwind," analysts at Credit Suisse said.The broker expects a 3.0% fall in sales and 4.0% decline in earnings per share (EPS) in the fourth quarter. About £50m of incremental vaccine tenders will offset some of the negatives in the quarter but many of the headwinds look set to continue into early 2013 including its products Cervarix, Vesicare, Lamictal XR, it added.Credit Suisse said a solid dividend yield of circa 5.0% will remain an attraction for the stock along with a free cash flow generation of circa £5.0bn per annum. "We forecast an ongoing £2.0bn per annum share buyback programme to double operational EPS growth of 3-6% [2012-16 compound annual growth rate]. However, we see limited opportunity for this to improve in the near term, in the absence of significant top line growth."Shares were down 0.91% to €5.57 at 16:02.INTERIMS Hargreaves Lansdown INTERIM DIVIDEND PAYMENT DATE Ashtead Group, Halma, Vodafone Group INTERIM EX-DIVIDEND DATE Cohort, Daejan Holdings, Ingenious Entertainment VCT 1, Ingenious Entertainment VCT 1 'C' Shares, Ingenious Entertainment VCT 1 'D' Shares, Ingenious Entertainment VCT 1 E Shares, Ingenious Entertainment VCT 1 F Shares, Ingenious Entertainment VCT 2, Ingenious Entertainment VCT 2 'C' Shares, Ingenious Entertainment VCT 2 'D' Shares, Ingenious Entertainment VCT 2 F Shares, Mattioli Woods, Penna Consulting, Puma High Income VCT , Puma Vct 8, Puma Vct VII, Stagecoach Group, Tricorn Group QUARTERLY EX-DIVIDEND DATE IBM Corp., JPMorgan Claverhouse Inv Trust, Unilever INTERNATIONAL ECONOMIC ANNOUNCEMENTS PMI Construction (GER) (08:55) Q3 Canaccord Financial Inc. Q4 GlaxoSmithKline, Virgin Media Inc., Wolfson Microelectronics FINALS GlaxoSmithKline, New Europe Property Investments, Virgin Media Inc., Wolfson Microelectronics IMSS Grainger SPECIAL EX-DIVIDEND PAYMENT DATE Rensburg AIM VCT AGMS Blackrock Income And Growth Investment Trust, LED International Holdings Ltd (DI), Redhall Group UK ECONOMIC ANNOUNCEMENTS BRC Shop Price Index (00:01) New Car Registrations (09:30) FINAL DIVIDEND PAYMENT DATE Edinburgh Worldwide Inv Trust FINAL EX-DIVIDEND DATE Noble Investments (UK), Victrex Thursday February 07 INTERIMS Mcbride INTERIM DIVIDEND PAYMENT DATE FirstGroup INTERNATIONAL ECONOMIC ANNOUNCEMENTS Consumer Credit (US) (20:00) ECB Interest Rate (EU) (12:45) Industrial Production (GER) (11:00) Productivity (US) (13:30) Q4 Smith & Nephew FINALS Beazley, Smith & Nephew IMSS Avon Rubber, Supergroup, Vodafone Group EGMS Hotel Corporation (The) AGMS Avon Rubber, BlackRock New Energy Inv Trust, Compass Group, Downing Absolute Income VCT 1, Downing Absolute Income VCT 1 'C' Shares , Downing Income Vct, Downing Income Vct 4, Paragon Group Of Companies, Thomas Cook Group, TUI Travel, Unicorn AIM VCT TRADING ANNOUNCEMENTS Bellway UK ECONOMIC ANNOUNCEMENTS Balance of Trade (09:30) BoE Interest Rate Decision (12:00) FINAL DIVIDEND PAYMENT DATE Cardiff Property, JPMorgan Asian Inv Trust Q1 TUI Travel, TUI Travel
More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.